Your browser doesn't support javascript.
loading
Decision-making about clinical trial options among older patients with metastatic cancer who have exhausted standard therapies.
Tsang, Mazie; DeBoer, Rebecca J; Garrett, Sarah B; Dohan, Daniel.
Affiliation
  • Tsang M; Division of Hematology/Oncology, University of California San Francisco, 505 Parnassus Avenue, Room M1286, Mailbox 1270, San Francisco, CA 94143, United States. Electronic address: Mazie.Tsang@ucsf.edu.
  • DeBoer RJ; Division of Hematology/Oncology, University of California San Francisco, 505 Parnassus Avenue, Room M1286, Mailbox 1270, San Francisco, CA 94143, United States. Electronic address: Rebecca.DeBoer@ucsf.edu.
  • Garrett SB; Institute for Health Policy Studies, University of California San Francisco, 490 Illinois Street, San Francisco, CA 94158, United States. Electronic address: Sarah.Garrett@ucsf.edu.
  • Dohan D; Institute for Health Policy Studies, University of California San Francisco, 490 Illinois Street, San Francisco, CA 94158, United States. Electronic address: Daniel.Dohan@ucsf.edu.
J Geriatr Oncol ; 13(5): 594-599, 2022 06.
Article in En | MEDLINE | ID: mdl-35125334
ABSTRACT

OBJECTIVES:

Older adults under-enroll in early phase cancer clinical trials. There are limited data on their trial experiences, which hampers our ability to understand potential reasons and responses to under-enrollment. We aimed to explore older adults' experiences and deliberations with phase 1 trials. MATERIALS AND

METHODS:

We analyzed 101 in-depth interviews with 39 adults (average 2.6 interviews per participant) about their experiences with phase 1 trials. All respondents were ≥ 65 years and had advanced cancer. Interviews lasted 60-90 min and were audio-recorded, transcribed, and analyzed to identify respondents' understanding of clinical research, perceptions of early phase trials, and experiences with enrollment.

RESULTS:

Clinical trial participation was an interactive process that unfolded over time. Older adults relied on ongoing guidance and discussion with their oncologist to navigate the process. Respondents were generally interested in life-prolonging therapies, including enrollment in early phase clinical trials, but did not necessarily state this explicitly to their oncologist. While respondents did not mention age as a limitation to trials participation, participants age > 70 were less enthusiastic about participation and more often discussed their quality of life and weighed benefits of trial participation in the context of their remaining months of life.

CONCLUSION:

Early phase clinical trial enrollment is complex, and older adults rely on their oncologist to navigate this process. Acknowledging this complexity through shared decision-making may ensure that older adults have appropriate opportunities to enroll in early phase clinical trials and guard against inappropriate under-enrollment.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quality of Life / Neoplasms Type of study: Guideline / Prognostic_studies / Qualitative_research Limits: Aged / Humans Language: En Journal: J Geriatr Oncol Year: 2022 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quality of Life / Neoplasms Type of study: Guideline / Prognostic_studies / Qualitative_research Limits: Aged / Humans Language: En Journal: J Geriatr Oncol Year: 2022 Type: Article